14 results match your criteria hba1c lp-pla2

  • Page 1 of 1

Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.

Clin Lab 2020 Oct;66(10)

Background: Diabetic foot (DF) is a common complication of diabetes with insidious onset, making it difficult for patients to receive timely diagnosis and treatment. This study aimed to evaluate the change in lipoprotein-associated phospholipase A2 (Lp-PLA2) and interleukin-18 (IL-18) in the serum of type 2 diabetes mellitus (T2DM) pa-tients with and without DF, thereby assessing the association between progression of DF and levels of Lp-PLA2 together with IL-18.

Methods: In this study, 50 patients with diabetes without foot ulcers (group I, T2DM group), 135 patients with diabetes with foot ulcers (group II, DF group), and 30 matched healthy controls (group III) were enrolled. Read More

View Article and Full-Text PDF
October 2020

Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.

Diabet Med 2020 01 5;37(1):75-83. Epub 2019 Aug 5.

Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center at Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

Aim: To assess the relevance of lipoprotein-associated phospholipase A2 activity as a diagnostic and prognostic marker for renal microvascular diseases.

Methods: We analysed lipoprotein-associated phospholipase A2 activity and lysophosphatidylcholine levels (as a surrogate marker of oxidative stress) in 165 adolescents (aged 17.0 ± 2. Read More

View Article and Full-Text PDF
January 2020

A 6-Week Worksite Positivity Program Leads to Greater Life Satisfaction, Decreased Inflammation, and a Greater Number of Employees With A1C Levels in Range.

J Occup Environ Med 2019 05;61(5):357-372

Employee Health & Benefits, Sarasota County Government, Sarasota (Dr Lord, Ms Deem, Ms Bray-Richarson); Aetna Inc., Tampa (Ms Pitchford); Florida Department of Health in Sarasota County (Mr Drennon), Sarasota, Florida.

Objective: To determine whether a 6-week Positivity Program could impact employee cardiovascular inflammation, blood sugars, cortisol, dehydroepiandrosterone (DHEA), and/or life satisfaction.

Methods: Pre- and post-study blood draw and life satisfaction questionnaire tracked changes in 10 cardiovascular and inflammatory biomarkers for 63 employees who participated in a 6-week Positivity Program comprised of three interventions: gratitude, HeartMath's Heart Lock-In, and yoga stretches with guided imagery.

Results: Improvements were recorded in life satisfaction as well as in seven of 10 cardiovascular and inflammatory biomarkers, including high sensitivity C-reactive protein (HsCRP) (-27%), hemoglobin A1c (HbA1c) (-1%), glucose (-2%), myeloperoxidase (MPO) (-5%), lipoprotein-associated phospholipase-A2 (Lp-PLA2) (-9%), apolipoprotein B (ApoB) (-6%), and DHEA (1%). Read More

View Article and Full-Text PDF

Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study.

Lipids Health Dis 2017 Mar 23;16(1):63. Epub 2017 Mar 23.

Department of Cardiology, the Eighty-first Hospital of PLA Affiliated with Anhui Medical University, No. 34, Biao 34, Yanggongjing, Qinhuai District, Nanjing, Jiangsu, 210000, China.

Background: Few data exist that correlate lesion-related risk factors such as conventional cardiovascular risks or lipoprotein-associated phospholipase A2 (Lp-PLA2) with tissue types within atherosclerotic plaques in patients with single-vessel and intermediate coronary lesions.

Methods: One hundred and ninety-two patients with single-vessel and intermediate coronary lesions were enrolled in a cross-sectional study and divided into two groups: stable angina pectoris (SAP) and acute coronary syndrome (ACS) groups. Data regarding clinical characteristics and Lp-PLA2 mass were collected. Read More

View Article and Full-Text PDF

Plasma Lipoprotein-Associated Phospholipase A₂ Levels Correlated with the Cardio-Ankle Vascular Index in Long-Term Type 2 Diabetes Mellitus Patients.

Authors:
Kazuhiko Kotani

Int J Mol Sci 2016 Apr 27;17(5). Epub 2016 Apr 27.

Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-City, Tochigi 329-0498, Japan.

The circulating levels of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) can be a simple, but practical and useful marker of cardiovascular disease (CVD). As limited studies are available in patients with diabetes mellitus (DM), further studies are needed to establish the clinical application of Lp-PLA₂ in DM practice. The present study investigated the correlation between Lp-PLA₂ and the cardio-ankle vascular index (CAVI), a recent marker of arterial stiffness, in DM patients according to their diabetes duration. Read More

View Article and Full-Text PDF

Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.

Atherosclerosis 2016 Apr 22;247:35-39. Epub 2016 Jan 22.

Background: There are conflicting reports on the role of fibrates in CVD-risk. Several studies indicate beneficial effects of fibrates on CVD risk in type-2 diabetic patients. We tested how fenofibrate changes lipoprotein subfractions and glucose homeostasis in type-2 diabetic patients. Read More

View Article and Full-Text PDF

Replacing carbohydrate with protein and fat in prediabetes or type-2 diabetes: greater effect on metabolites in PBMC than plasma.

Nutr Metab (Lond) 2016 19;13. Epub 2016 Jan 19.

Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, 03722 Republic of Korea ; National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, 03722 Republic of Korea ; Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722 Republic of Korea.

Background: Active metabolism of peripheral blood mononuclear cells (PBMC) could suggest their suitability for metabolomics studies. This study examined whether reductions in PBMCs and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activities induced by dietary intervention affected the overall metabolic profiles of PBMC and plasma.

Methods: Eighty nonobese subjects aged 40-70 years (18. Read More

View Article and Full-Text PDF
January 2016

Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.

Acta Med Iran 2015 Nov;53(11):690-6

Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is produced by inflammatory cells, bound to LDL and other lipoproteins, and hydrolyzes oxidized phospholipids in LDL. Type 2 diabetes is the most common form of diabetes some investigations show the association of lipoprotein-associated phospholipase A2 mass and activity with the incidence of cardiovascular disease (CVD) in populations with high prevalences of insulin resistance and diabetes. This study is a cross-sectional descriptive and analytic study on 80 individuals with diabetes referring to the Tehran Diabetes Association. Read More

View Article and Full-Text PDF
November 2015

Novel metabolic biomarkers of cardiovascular disease.

Nat Rev Endocrinol 2014 Nov 2;10(11):659-72. Epub 2014 Sep 2.

Department of Medicine, Beth Israel Deaconess Medical Centre, 1309 Beacon Street, 02446 Brookline, MA, USA.

Coronary heart disease (CHD) accounts for one in every six deaths in US individuals. Great advances have been made in identifying important risk factors for CHD, such as hypertension, diabetes mellitus, smoking and hypercholesterolaemia, which have led to major developments in therapy. In particular, statins represent one of the greatest successes in the prevention of CHD. Read More

View Article and Full-Text PDF
November 2014

Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease.

Eur J Intern Med 2014 Jul 12;25(6):556-60. Epub 2014 Jun 12.

Department of Clinical Biochemistry and Hematology, University Hospital Pilsen, Czech Republic.

Background: Elevated lipoprotein-associated phospholipase A2 activity (aLp-PLA2) is associated with increased risk of cardiovascular events. In patients with stable atherovascular disease, we aimed to investigate whether impaired glucose metabolism might be associated with higher risk of elevated aLp-PLA2.

Methods: We conducted a cross-sectional study in 825 stable patients after acute coronary syndrome, coronary revascularization or after first ischemic stroke (Czech part of EUROASPIRE III surveys). Read More

View Article and Full-Text PDF

Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.

Int J Cardiovasc Imaging 2012 Apr 19;28(4):695-703. Epub 2011 May 19.

Thoraxcenter, Erasmus MC, Ba583, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.

We explored the impact of patient demographics, anthropometric measurements, cardiovascular risk factors, and soluble biomarkers on necrotic core and atheroma size in patients with coronary disease. The IBIS-2 trial enrolled 330 patients. In the multivariate analysis, at baseline, creatinine had a positive, whereas baseline mean lumen diameter and myeloperoxidase had a negative, independent association with percentage of necrotic core (PNC); while age, glomerular filtration rate <60, HbA1c, previous PCI or CABG and baseline % diameter stenosis were positively, and acute coronary syndromes (ACS) were negatively associated with baseline percentage atheroma volume (PAV). Read More

View Article and Full-Text PDF

Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.

Prostaglandins Other Lipid Mediat 2008 Dec 31;87(1-4):42-6. Epub 2008 Jul 31.

Department of Medicine, Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Plasma activity of the platelet-activating factor acetylhydrolase (PAF-AH) plays an important role in inflammation and atherosclerotic process in chronic diseases. We aimed to evaluate the levels of PAF-AH activity and their association with the metabolic profile and chronic complications in patients with type 1 diabetes. The study included 118 outpatients (54 males) aged 27. Read More

View Article and Full-Text PDF
December 2008

Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.

Arq Bras Cardiol 2007 Feb;88(2):179-84

Serviço de Diabetes, Hospital Pedro Ernesto, UERJ, Rio de Janeiro, RJ, Brazil.

Objective: To evaluate platelet-activating factor acetylhydrolase (PAF-AH) activity and its relationship with clinical and demographic variables, metabolic control, apolipoprotein A and B levels and the susceptibility of low-density lipoprotein (LDL) to in vitro oxidation in patients with type 1 diabetes mellitus (DM 1).

Methods: Forty two patients with DM 1 (27 females) and 48 control subjects (16 females) matched for gender, age and body mass index (BMI) were evaluated. The following tests were performed: fast plasma glucose (FG) and postprandial plasma glucose (PPG), lipid profile, uric acid (UA), glycosylated hemoglobin (HbA1c), and low-density lipoprotein (LDL) oxidation rate using colorimetric assay. Read More

View Article and Full-Text PDF
February 2007

Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus.

Am J Cardiol 2007 Feb 20;99(4A):80B-88B. Epub 2006 Dec 20.

Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.

The identification of individuals at increased risk for cardiovascular disease (CVD) events is the critical first step toward reducing CVD morbidity and mortality. Accurate models for cardiac risk stratification benefit high-risk patients, who stand to gain the most from aggressive treatments, including pharmacologic therapies for blood pressure control, lipid lowering, glycemic control, and smoking cessation, as well as lower risk patients, who may avoid the added expense and complications from unnecessary medications and procedures. The further stratification of CVD risk in patients with diabetes mellitus may be important in individualizing therapy and in developing future clinical trials to examine new approaches for CVD event reduction in patients with diabetes. Read More

View Article and Full-Text PDF
February 2007
  • Page 1 of 1